Physician

James W Lee, MD

According to 2025 Medicare claims, James Lee, MD (NPI: 1073527560) practices hematology/oncology in the Camden, NJ market, with the plurality of this provider's patient population coming from Burlington, NJ. This provider's primary affiliated billing organization is REGIONAL CANCER CARE ASSOCIATES LLC (NPI: 1801850243; TIN: 223141761) and primary practice location at 08057-3146.

Lee's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 343 traditional Medicare patients, billed 117,094 HCPCS/CPT codes, and received $2,018,798 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,236 prescription claims across 176 beneficiaries totaling $2,111,201 in drug costs, led by Revlimid (Lenalidomide). 2018 DME data shows 11 claims. Open Payments data shows 3 records totaling $36. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have changed little. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	304	78,360	$1,556,929
2016	394	134,904	$2,258,711
2017	388	124,465	$2,363,161
2018	381	169,252	$2,985,822
2019	308	125,575	$2,387,466
2020	329	126,892	$2,017,848
2021	344	136,795	$1,907,793
2022	362	90,331	$1,688,177
2023	349	91,718	$2,066,381
2024	343	117,094	$2,018,798

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	114	920	$1,429,939
2016	149	1,375	$1,943,529
2017	161	1,424	$1,875,672
2018	158	1,510	$1,837,195
2019	139	1,442	$1,694,955
2020	159	1,272	$1,514,927
2021	164	1,341	$2,211,953
2022	157	1,402	$1,883,096
2023	157	1,345	$2,393,528
2024	176	1,236	$2,111,201

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	99	$25,786
2016	N/R	105	$30,590
2017	N/R	25	$2,044
2018	N/R	11	$1,028
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	96	236	$148
96413	Administration of chemotherapy into vein, 1 hour or less	57	258	$108
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	216	509	$102
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	97	307	$13
96372	Injection of drug or substance under skin or into muscle	79	242	$11

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	31	868	$491,178
Xtandi	Enzalutamide	35	1,050	$442,392
Pomalyst	Pomalidomide	18	504	$401,465
Tagrisso	Osimertinib Mesylate	11	330	$187,786
Eliquis	Apixaban	19	974	$17,850

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	2	$36	GENZYME CORPORATION
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	1	$5,000	Cornerstone Specialty Network LLC

Explore More Providers

FAQ

What Medicare data is available for James W. Lee, MD?

Tedicare shows public-source Medicare data for James W. Lee, MD (NPI 1073527560), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does James W. Lee, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to James W. Lee, MD?

James W. Lee, MD is linked to REGIONAL CANCER CARE ASSOCIATES LLC (billing NPI 1801850243) in the available physician profile data.

Does James W. Lee, MD have Open Payments data?

James W. Lee, MD has 3 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.